Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ATP4A | P20648 | 5/20 | 0.37 |
| ▸ | ATP4B | P51164 | 5/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690888 | 1.00 | RAB9A (0.41) | RAB9ASMN1; SMN2ALDH1A1KDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL1002426 | 0.98 | RAB9A (0.43) | RAB9ASMN1; SMN2ALDH1A1KDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL28857260 | 0.98 | RAB9A (0.43) | RAB9ASMN1; SMN2ALDH1A1KDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL29362717 | 0.98 | RAB9A (0.43) | RAB9ASMN1; SMN2ALDH1A1KDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL28044243 | 0.90 | RAB9A (0.39) | RAB9ASMN1; SMN2ALDH1A1KDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL3169911 | 0.88 | RAB9A (0.37) | RAB9ASMN1; SMN2ALDH1A1KDM4ETDP1 | |
| SCHEMBL1004190 | 0.82 | RAB9A (0.42) | RAB9ASMN1; SMN2ALDH1A1KDM4EATP4A | |
| SCHEMBL30963126 | 0.82 | RAB9A (0.42) | RAB9ASMN1; SMN2ALDH1A1KDM4EATP4A | |
| SCHEMBL11918960 | 0.82 | RAB9A (0.42) | RAB9ASMN1; SMN2ALDH1A1KDM4EATP4A | |
| Hydrochloric Acid SCHEMBL3170719 | 0.82 | RAB9A (0.33) | RAB9ASMN1; SMN2ALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728019-A1 | A MICROWAVE CARBONIZATION ASSEMBLY AND METHOD FOR EXTRACTING COMPONENTS FROM RUBBER | Sable Rubber IP Pty Limited (AU) | 2026-04-22 | — | — | EP | disclosed |
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024257019-A1 | A MICROWAVE CARBONIZATION ASSEMBLY AND METHOD FOR EXTRACTING COMPONENTS FROM RUBBER | Molectra Rubber IP Pty Ltd (AU) | 2024-12-19 | — | — | WO | disclosed |
| CN-115867546-B | Salt and crystalline forms of GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024216094-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | SOLEY THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-118324772-A | Synthesis method and intermediate of furan [3,2-b ] pyridine derivative | 北京颖诺凯胜科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117715906-A | Glucagon-like peptide-1 receptor modulators and uses thereof | 和博医药有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117043154-A | GPCR receptor agonists, pharmaceutical compositions comprising same, and methods of use thereof | 卡莫特医疗有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116507326-A | Compounds as GLP-1R agonists | 拓臻制药公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | US | disclosed |
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| CN-114213424-B | Synthesis method of furan [3,2-b ] pyridine derivative | 杭州高光制药有限公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-115867546-A | Salts and crystalline forms of GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-03-21 | — | — | US | disclosed |
| CN-115697999-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-114685514-A | Novel amide pyrrole compound and application thereof in medicines | 广东东阳光药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | RAB9A 1238/4885SMN1; SMN2 4595/4885ALDH1A1 2010/4885 |
| US-11608341-B2 | Substituted tetrahydropyrazolo[3,4-d]pyrimidines and tetrahydropyrazolo[4,3-d]pyrimidines as C5A receptor modulators | C5AR1, C3AR1, C5AR2 | RAB9A 1399/4885SMN1; SMN2 4565/4885ALDH1A1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.